Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With December Approaching, Are More Turkish Price Cuts On The Way?

This article was originally published in The Pink Sheet Daily

Executive Summary

The government of the world's 12th-largest pharmaceutical market has enforced steep price cuts on drugs in each of the last two years, both times in December.

You may also be interested in...

Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues

Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker

Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets

Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts

Boehringer Threatens Turkish Exit Due To Price Cuts

German drug maker Boehringer Ingelheim GMBH, dismayed by profit declines caused by a series of price cut measures enforced by the Turkish government, has indicated it is considering quitting the Turkish market, but it still hopes to continue research and investment in one of the fastest growing pharmaceutical markets

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts